Developer docs
API playgroundTry for free, no card

Search company profiles

Future Fields

Full company profile

uuid0000c24

Namestring
Future Fields
Legal namestring
Future Fields
Websiteurl
futurefields.io
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Future Fields is an Edmonton, Canada-based biotechnology company founded in 2018 that has developed the EntoEngine™, a proprietary biomanufacturing platform using transgenic Drosophila melanogaster (fruit flies) as whole-insect bioreactors for recombinant protein production. The platform is purpose-built for difficult-to-express proteins (DTEPs) — proteins that conventional E. coli, yeast, and CHO cell systems fail to produce — and offers multicellular expression across 200+ distinct cell types, inducible expression for toxic proteins, stable expression strains maintained via balancer chromosomes, glycosylation without immunogenic α1,3-fucosylation, and demonstrated CHO-equivalent yields of up to 305 g/L with 86% lower carbon emissions and 74% lower water usage than conventional methods.

The company operates as a Contract Development and Manufacturing Organization (CDMO), providing custom protein production services through a four-stage milestone-based process (Strain Generation, Expression Optimization, Process Development, Production & Characterization) under bespoke, quote-based, multi-year contracts. A secondary revenue stream consists of catalog recombinant protein reagents — growth factors (including FGF2, the first growth factor to receive the ACT Environmental Impact Factor Label), hormones, and cytokines — sold direct to life sciences customers. Customers span four verticals: life sciences/biopharma (cancer and immune-disorder therapeutics, cell/gene therapy ancillary materials, AI-designed proteins), crop sciences/agriculture (insecticidal proteins and Plant-Incorporated Protectants), food innovation/cellular agriculture (growth factors for cultivated meat), and AI protein design companies (manufacturing partner for computationally designed sequences).

Commercial operations run through direct, consultative enterprise sales led by a dedicated business development team, with inbound driven by a "Request a protein consult" CTA on the company website. The company has raised over $15M USD across multiple rounds — most recently an oversubscribed $8M Series A in June 2025 co-led by Amplify Capital, BDC Climate Tech Fund, and R7 Partners — and operates from a 6,000-square-foot Instar 1.0 biofactory in downtown Edmonton that opened in November 2024 and is staffed by 20+ technicians, chemists, and biomolecular specialists. Distribution is entirely direct, with no channel partners.

Short descriptiontext

Future Fields is an Edmonton-based biotech CDMO using transgenic fruit flies (EntoEngine™ platform) to produce difficult-to-express recombinant proteins for biopharma, crop sciences, food innovation, and AI protein design clients, operating from a 6,000 sq ft commercial biofactory.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEdmonton, Canada
HQ citystring
Edmonton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
recombinant protein production, insect-based biomanufacturing, CDMO services, transgenic protein expression, biopharmaceutical manufacturing
Industry1 code
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical CDMO Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Custom Protein Production Services (CDMO)
TypeProfessional Services
Description

Future Fields acts as a contract development and manufacturing organization (CDMO), providing custom recombinant protein production services using the EntoEngine platform. Clients commission Future Fields to manufacture bespoke proteins designed for cutting edge research and therapeutic development. Services follow a milestone-based process: Strain Generation, Expression Optimization, Process Development, and Production & Characterization. Pricing is quote-based given the bespoke nature of each engagement.

futurefields.io
2Recombinant Protein Reagent Products
TypeOne Time License
Description

Future Fields sells catalog recombinant protein products including growth factors (FGF2, EGF), hormones (prolactin, etc.), and cytokines for biomedical research and biopharma. FGF2 products were the first growth factors in the world to receive the ACT Environmental Impact Factor Label. Products are sold directly to life sciences customers.

futurefields.io
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others
Pricing details1 tier
1Custom Protein Production Services — bespoke, quote-based engagements
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is negotiated on a per-project basis depending on protein complexity, volume requirements, and timeline. No standard price list is publicly available.

futurefields.io
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1EntoEngine™
Description

Proprietary transgenic Drosophila melanogaster-based protein expression platform for producing recombinant proteins at scale

futurefields.io
+1 more record
Core offering1 text field

Future Fields operates as a Contract Development and Manufacturing Organization (CDMO) that uses transgenic Drosophila melanogaster (fruit flies) as whole-insect bioreactors to produce recombinant proteins. Through its proprietary EntoEngine™ platform, the company provides custom protein production services for life sciences, agriculture, and food innovation clients, specializing in difficult-to-express proteins (DTEPs) that conventional systems (E. coli, yeast, CHO cells) cannot make.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 86% less carbon emissions and 74% less water usage compared to conventional bioreactor-based protein production
+7 more records
Product overview1 text field

Future Fields operates as a biotech CDMO offering the EntoEngine™ Platform as its core technology, which uses transgenic Drosophila melanogaster (fruit flies) as whole-insect bioreactors for recombinant protein production. The company provides Custom Protein Production Services including Life Sciences and Crop Sciences offerings, with the Instar 1.0 Biofactory as the manufacturing facility enabling commercial-scale production. Product portfolio includes recombinant protein reagents for research and biopharma applications, alongside novel exotic tissue-specific protein expression services for next-generation disease research. The company positions itself as a sustainable alternative to conventional bioreactors, serving agriculture, food innovation, and biopharma markets.

Product and service3 records
1Custom Protein Production Services
CategoryCDMO Services
Description

Custom protein production services leveraging genetically engineered fruit flies to express high-quality recombinant proteins at scale, following a milestone-based process: Strain Generation, Expression Optimization, Process Development, and Production & Characterization. Targets life sciences, crop sciences, and food innovation clients.

2Crop Sciences Services
3Recombinant Protein Reagents
CategoryResearch Reagents
Description

Catalog of recombinant protein products including growth factors (FGF2, EGF), hormones (prolactin), and cytokines for biomedical research and biopharma applications, produced via the EntoEngine platform.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-17
Description

Strategic partnership announced with Protein Evolution to produce AI-engineered proteins. As part of this partnership, Future Fields will manufacture computationally designed proteins created by Protein Evolution's AI platform, combining AI protein design with biomanufacturing capabilities to bring novel therapeutics and research tools to market.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-05-10
Description

John Cumbers, founder and CEO of SynBioBeta (the premier innovation network for biological engineers, entrepreneurs, and investors), joined Future Fields' advisory board. SynBioBeta hosts the annual SynBioBeta Conference where Future Fields gains visibility.

Strategic tierMinorTypeOthersAnnounced on2022-12-06
Description

Future Fields is the first Canadian recombinant protein manufacturer to join the UN Global Compact initiative, committing to ten universally accepted principles in human rights, labour, environment, and anti-corruption.

4Dr. Michael Houghton (Nobel Laureate)
Strategic tierMinorTypeOthersAnnounced on2022-08-15
Description

Dr. Michael Houghton, co-discoverer of the hepatitis C virus and 2020 Nobel Prize Laureate in Physiology or Medicine, joined Future Fields' advisory board. He brings over 40 years of expertise in recombinant protein production for clinical applications.

futurefields.io
Strategic tierMinorTypeOthers
Description

Future Fields is a proud business member of 1% for the Planet, pledging to donate 1% of annual sales to nonprofit environmental organizations.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Canadian biotech platform leveraging AI and high-throughput biology for antibody discovery and development. Comparable as a Canadian-headquartered biotech services company targeting biopharma innovation; overlaps with Future Fields in serving AI-driven protein discovery workflows.

TypeBroad incumbent
Description

Large-scale biologics CDMO offering custom protein and antibody manufacturing services. Competes for the same biopharma outsourcing dollars as Future Fields, but at vastly larger scale and with established mammalian platforms.

TypeBroad incumbent
Description

Global leader in biologics CDMO services with mammalian cell-based protein production. Comparable as a major recombinant protein manufacturing services provider for pharma, though Future Fields competes by offering a fundamentally different expression host (insect vs. mammalian) at lower cost and carbon footprint.

TypeBroad incumbent
Description

Major CDMO providing biologics development, manufacturing, and analytical services. Comparable as a custom protein production services provider, though Future Fields positions against Catalent's incumbent mammalian and microbial platforms with a novel insect-based alternative.

TypeEmerging player
Description

Synthetic biology platform company offering cell programming and biomanufacturing services. Comparable as a synbio services provider targeting diverse end markets including agriculture and food, similar to Future Fields' vertical diversification strategy.

TypeDirect peer
Description

Specialized CDMO providing custom recombinant protein and biologics manufacturing services for biopharma clients, including difficult-to-express proteins. Closely comparable business model as a custom services provider to small-to-medium biopharma companies.

7Culture Biosciences
TypeEmerging player
Description

Biomanufacturing company offering custom fermentation and protein production services with a technology-forward platform. Comparable as a smaller, technology-enabled CDMO targeting biopharma and synthetic biology clients with innovative service delivery.

TypeBroad incumbent
Description

Global biologics CDMO providing end-to-end custom protein and antibody manufacturing. Comparable business model as a CDMO for biopharma, but operates at industrial scale with CHO-based platforms; notable for being a primary competitor mentioned in company materials about geopolitical supply chain risk.

TypeDirect peer
Description

Recombinant protein catalog and custom manufacturing company producing growth factors, cytokines, and research-use proteins for life sciences. Comparable as a recombinant protein product company serving biomedical research and biopharma; relevant because Future Fields has hired PeproTech veterans.

TypeBroad incumbent
Description

Global life sciences services group with CDMO and bioanalytical capabilities, including protein production. Comparable as a large commercial services provider in life sciences, though at vastly greater scale and breadth than Future Fields' specialized platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Future Fields

Biopharmaceutical CDMO Servicesfuturefields.io

Future Fields is an Edmonton-based biotech CDMO using transgenic fruit flies (EntoEngine™ platform) to produce difficult-to-express recombinant proteins for biopharma, crop sciences, food innovation, and AI protein design clients, operating from a 6,000 sq ft commercial biofactory.

What Future Fields does

Future Fields is an Edmonton, Canada-based biotechnology company founded in 2018 that has developed the EntoEngine™, a proprietary biomanufacturing platform using transgenic Drosophila melanogaster (fruit flies) as whole-insect bioreactors for recombinant protein production. The platform is purpose-built for difficult-to-express proteins (DTEPs) — proteins that conventional E. coli, yeast, and CHO cell systems fail to produce — and offers multicellular expression across 200+ distinct cell types, inducible expression for toxic proteins, stable expression strains maintained via balancer chromosomes, glycosylation without immunogenic α1,3-fucosylation, and demonstrated CHO-equivalent yields of up to 305 g/L with 86% lower carbon emissions and 74% lower water usage than conventional methods.

The company operates as a Contract Development and Manufacturing Organization (CDMO), providing custom protein production services through a four-stage milestone-based process (Strain Generation, Expression Optimization, Process Development, Production & Characterization) under bespoke, quote-based, multi-year contracts. A secondary revenue stream consists of catalog recombinant protein reagents — growth factors (including FGF2, the first growth factor to receive the ACT Environmental Impact Factor Label), hormones, and cytokines — sold direct to life sciences customers. Customers span four verticals: life sciences/biopharma (cancer and immune-disorder therapeutics, cell/gene therapy ancillary materials, AI-designed proteins), crop sciences/agriculture (insecticidal proteins and Plant-Incorporated Protectants), food innovation/cellular agriculture (growth factors for cultivated meat), and AI protein design companies (manufacturing partner for computationally designed sequences).

Commercial operations run through direct, consultative enterprise sales led by a dedicated business development team, with inbound driven by a "Request a protein consult" CTA on the company website. The company has raised over $15M USD across multiple rounds — most recently an oversubscribed $8M Series A in June 2025 co-led by Amplify Capital, BDC Climate Tech Fund, and R7 Partners — and operates from a 6,000-square-foot Instar 1.0 biofactory in downtown Edmonton that opened in November 2024 and is staffed by 20+ technicians, chemists, and biomolecular specialists. Distribution is entirely direct, with no channel partners.

Future Fields firmographics

Firmographics
Name
Future Fields
Legal name
Future Fields
Website
https://futurefields.io
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Future Fields is an Edmonton-based biotech CDMO using transgenic fruit flies (EntoEngine™ platform) to produce difficult-to-express recombinant proteins for biopharma, crop sciences, food innovation, and AI protein design clients, operating from a 6,000 sq ft commercial biofactory.
Ownership category
akta.pro rank

Future Fields industry classification

Industry
Product category
Biopharmaceutical CDMO Services
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Recombinant protein production
  • Insect-based biomanufacturing
  • CDMO services
  • Transgenic protein expression
  • Biopharmaceutical manufacturing

Where Future Fields is headquartered

Location

Headquarters

HQ city
Edmonton
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Future Fields business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Custom Protein Production Services (CDMO): Future Fields acts as a contract development and manufacturing organization (CDMO), providing custom recombinant protein production services using the EntoEngine platform. Clients commission Future Fields to manufacture bespoke proteins designed for cutting edge research and therapeutic development. Services follow a milestone-based process: Strain Generation, Expression Optimization, Process Development, and Production & Characterization. Pricing is quote-based given the bespoke nature of each engagement.
  2. Recombinant Protein Reagent Products: Future Fields sells catalog recombinant protein products including growth factors (FGF2, EGF), hormones (prolactin, etc.), and cytokines for biomedical research and biopharma. FGF2 products were the first growth factors in the world to receive the ACT Environmental Impact Factor Label. Products are sold directly to life sciences customers.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom Protein Production Services — bespoke, quote-based engagements

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Future Fields product offering

Product offering

Core offering

Future Fields operates as a Contract Development and Manufacturing Organization (CDMO) that uses transgenic Drosophila melanogaster (fruit flies) as whole-insect bioreactors to produce recombinant proteins. Through its proprietary EntoEngine™ platform, the company provides custom protein production services for life sciences, agriculture, and food innovation clients, specializing in difficult-to-express proteins (DTEPs) that conventional systems (E. coli, yeast, CHO cells) cannot make.

Product overview

Future Fields operates as a biotech CDMO offering the EntoEngine™ Platform as its core technology, which uses transgenic Drosophila melanogaster (fruit flies) as whole-insect bioreactors for recombinant protein production. The company provides Custom Protein Production Services including Life Sciences and Crop Sciences offerings, with the Instar 1.0 Biofactory as the manufacturing facility enabling commercial-scale production. Product portfolio includes recombinant protein reagents for research and biopharma applications, alongside novel exotic tissue-specific protein expression services for next-generation disease research. The company positions itself as a sustainable alternative to conventional bioreactors, serving agriculture, food innovation, and biopharma markets.

Differentiator

Problem solved

Functional benefit

Brands

  • EntoEngine™: Proprietary transgenic Drosophila melanogaster-based protein expression platform for producing recombinant proteins at scale
  • Instar 1.0

Products and services

  • Custom Protein Production Services Custom protein production services leveraging genetically engineered fruit flies to express high-quality recombinant proteins at scale, following a milestone-based process: Strain Generation, Expression Optimization, Process Development, and Production & Characterization. Targets life sciences, crop sciences, and food innovation clients.
  • Crop Sciences Services
  • Recombinant Protein Reagents Catalog of recombinant protein products including growth factors (FGF2, EGF), hormones (prolactin), and cytokines for biomedical research and biopharma applications, produced via the EntoEngine platform.

Quantifiable outcome

  • 86% less carbon emissions and 74% less water usage compared to conventional bioreactor-based protein production
  • +7 more outcomes

Companies that use Future Fields

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Future Fields technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Future Fields partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Protein EvolutioncoreStrategic or Co-development Partner · 17 June 2025Strategic partnership announced with Protein Evolution to produce AI-engineered proteins. As part of this partnership, Future Fields will manufacture computationally designed proteins created by Protein Evolution's AI platform, combining AI protein design with biomanufacturing capabilities to bring novel therapeutics and research tools to market.
  • John Cumbers / SynBioBetaminorStrategic or Co-development Partner · 10 May 2023John Cumbers, founder and CEO of SynBioBeta (the premier innovation network for biological engineers, entrepreneurs, and investors), joined Future Fields' advisory board. SynBioBeta hosts the annual SynBioBeta Conference where Future Fields gains visibility.
  • United Nations Global CompactminorOthers · 6 December 2022Future Fields is the first Canadian recombinant protein manufacturer to join the UN Global Compact initiative, committing to ten universally accepted principles in human rights, labour, environment, and anti-corruption.
  • Dr. Michael Houghton (Nobel Laureate)minorOthers · 15 August 2022Dr. Michael Houghton, co-discoverer of the hepatitis C virus and 2020 Nobel Prize Laureate in Physiology or Medicine, joined Future Fields' advisory board. He brings over 40 years of expertise in recombinant protein production for clinical applications.
  • 1% for the PlanetminorOthersFuture Fields is a proud business member of 1% for the Planet, pledging to donate 1% of annual sales to nonprofit environmental organizations.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Future Fields competitors and assessment

Company assessment

Emerging players

  • AbCellera Biologics: Canadian biotech platform leveraging AI and high-throughput biology for antibody discovery and development. Comparable as a Canadian-headquartered biotech services company targeting biopharma innovation; overlaps with Future Fields in serving AI-driven protein discovery workflows.
  • Ginkgo Bioworks: Synthetic biology platform company offering cell programming and biomanufacturing services. Comparable as a synbio services provider targeting diverse end markets including agriculture and food, similar to Future Fields' vertical diversification strategy.
  • Culture Biosciences: Biomanufacturing company offering custom fermentation and protein production services with a technology-forward platform. Comparable as a smaller, technology-enabled CDMO targeting biopharma and synthetic biology clients with innovative service delivery.

Broad incumbents

  • Samsung Biologics: Large-scale biologics CDMO offering custom protein and antibody manufacturing services. Competes for the same biopharma outsourcing dollars as Future Fields, but at vastly larger scale and with established mammalian platforms.
  • Lonza Group: Global leader in biologics CDMO services with mammalian cell-based protein production. Comparable as a major recombinant protein manufacturing services provider for pharma, though Future Fields competes by offering a fundamentally different expression host (insect vs. mammalian) at lower cost and carbon footprint.
  • Catalent: Major CDMO providing biologics development, manufacturing, and analytical services. Comparable as a custom protein production services provider, though Future Fields positions against Catalent's incumbent mammalian and microbial platforms with a novel insect-based alternative.
  • WuXi Biologics: Global biologics CDMO providing end-to-end custom protein and antibody manufacturing. Comparable business model as a CDMO for biopharma, but operates at industrial scale with CHO-based platforms; notable for being a primary competitor mentioned in company materials about geopolitical supply chain risk.
  • Eurofins Scientific: Global life sciences services group with CDMO and bioanalytical capabilities, including protein production. Comparable as a large commercial services provider in life sciences, though at vastly greater scale and breadth than Future Fields' specialized platform.

Direct peers

  • AGC Biologics: Specialized CDMO providing custom recombinant protein and biologics manufacturing services for biopharma clients, including difficult-to-express proteins. Closely comparable business model as a custom services provider to small-to-medium biopharma companies.
  • PeproTech: Recombinant protein catalog and custom manufacturing company producing growth factors, cytokines, and research-use proteins for life sciences. Comparable as a recombinant protein product company serving biomedical research and biopharma; relevant because Future Fields has hired PeproTech veterans.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Future Fields social profiles

Digital presence

Future Fields compliance and trust

Trust signal

Compliance4 records

Future Fields financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Future Fields leadership team

Management profile

Number of profiles

Profiles14 records

Future Fields funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Future Fields M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Future Fields

What does Future Fields do?

Future Fields operates as a Contract Development and Manufacturing Organization (CDMO) that uses transgenic Drosophila melanogaster (fruit flies) as whole-insect bioreactors to produce recombinant proteins. Through its proprietary EntoEngine™ platform, the company provides custom protein production services for life sciences, agriculture, and food innovation clients, specializing in difficult-to-express proteins (DTEPs) that conventional systems (E. coli, yeast, CHO cells) cannot make.

Is Future Fields a public or private company?

Future Fields is a private company. It is classified as venture growth investor backed and is currently operating.

When was Future Fields founded?

Future Fields was founded in 2018. It employs 11 to 50 people.

Where is Future Fields based?

Future Fields is headquartered in Edmonton, Canada, in the North America region.

How does Future Fields make money?

Two revenue lines are on record. Custom Protein Production Services (CDMO) is the primary driver. The others are recombinant Protein Reagent Products.

Who are Future Fields's main competitors?

Emerging players on record are AbCellera Biologics, Ginkgo Bioworks and Culture Biosciences. Broad incumbents are Samsung Biologics, Lonza Group, Catalent, WuXi Biologics and Eurofins Scientific. Direct peers are AGC Biologics and PeproTech.

Does Future Fields have an API?

No public API is recorded for Future Fields.

What industry is Future Fields in?

Future Fields's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SynBioBetaWhy Flies? Inside Future Fields' Bet on Insect-Based Protein ManufacturingFuture Fields, an Edmonton biomanufacturing company, developed EntoEngine, a recombinant protein expression system using the fruit fly Drosophila melanogaster. The platform targets difficult-to-express proteins, aiming to cut scaling timelines to under seven months and reduce costs. The company plans to scale 200 times by late 2026 and expand into cell therapy and in vitro diagnostics.FuturefieldsFuture Fields Debuts Instar 1.0: A Biofactory With 30 Times the Output of Conventional Protein TechnologyFuture Fields has launched Instar 1.0, a biofactory technology that reportedly delivers 30 times the output of conventional protein production methods. This innovation marks a significant advancement in protein technology, potentially impacting the industry by enhancing production efficiency. Looking ahead, this development may transform how protein is produced at scale.FuturefieldsFuture Fields Debuts Instar 1.0: A Biofactory With 30 Times the Output of Conventional Protein TechnologyFuture Fields launched Instar 1.0, a new biomanufacturing facility in Edmonton that utilizes fruit fly biotechnology to produce recombinant proteins with significantly higher output and lower environmental impact than conventional methods. The company is expanding its service line to include custom production of exotic tissue-specific proteins to meet growing demand from the biotech sector, particularly driven by North American supply chain needs.Business Wire BlogFuture Fields and Jenthera Therapeutics Collaborate to Develop Novel Protein for the Delivery of Cancer BiologicsFuture Fields and Jenthera Therapeutics announced a collaboration to produce a novel cancer-fighting protein using Future Fields' fruit-fly-based EntoEngine platform. The partnership aims to mass-produce the protein more sustainably and cost-effectively than conventional biopharmaceutical methods. Jenthera will use the protein for its CRISPR ribonucleoprotein delivery system.FinSMEsFuture Fields Raises $11.2M USD in FundingFuture Fields, an Edmonton-based fly biotechnology company, raised $11.2 million USD in a funding round led by Bee Partners and Toyota Ventures. The company plans to use the capital to hire key personnel and construct its first production facility in Canada for manufacturing recombinant proteins at kilogram scale.TechCrunchFuture Fields is turning fruit flies into bioreactorsFuture Fields announced $11.2 million in seed extension funding to build a production facility for its EntoEngine, which uses fruit flies to produce recombinant proteins. The company says its fly-based system is 16-30 times faster than traditional bioreactors and has shipped animal protein to over 60 companies. It plans to scale production at kilogram scale in 10,000 square feet.BetaKitFuture Fields raises $15.1 million CAD to equip more industries with bioreactors made from fliesEdmonton-based biotech startup Future Fields raised $15.1 million CAD in a seed extension funding round to expand its fruit fly-based bioreactor technology into medical research and biopharmaceuticals. The company, which counts Toyota Ventures and Bee Partners among its investors, intends to use the capital to hire personnel and construct a production facility in Edmonton capable of kilogram-scale recombinant protein output.Financial PostBioAlberta Recognizes Alberta Innovators and Entrepreneurs at Annual Health and Life Sciences Showcase & Awards CeremonyBioAlberta presented its 2022 Achievement Awards at a Calgary ceremony on September 27, recognizing Future Fields, Dr. Toshima Yokota, and Dr. Hasan Uludag. Future Fields won Company of the Year for its insect-based recombinant protein platform, while the other two recipients were honored for scientific breakthroughs in muscular dystrophy and bone-targeted drug delivery.University of Calgary in AlbertaHaskayne launches ScaleUp program to help Alberta companies compete globallyHaskayne School of Business launched a nine-month ScaleUp program to help high-growth Alberta companies scale globally. The first cohort includes cleantech firms like CleanO2 and Future Fields, with a goal of five times revenue or capital growth within 24-36 months. Partners include HSBC, Deloitte Canada, and Fasken.foodnavigator-usa.comCould fruit flies slash the cost of growth media for cell cultured meat? Future Fields thinks outside the boxFuture Fields is developing a fruit-fly-based system to produce recombinant proteins for cell-cultured meat growth media. The company claims a nine-and-a-half-fold reduction in CO2 emissions and lower production costs compared to microbial systems. It aims to produce hundreds of kilos of protein per month by 2024.